Arcutis Biotherapeutics (ARQT) Cash from Investing Activities (2019 - 2026)

Arcutis Biotherapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$11.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 196.44% year-over-year to -$11.3 million; the TTM figure through Mar 2026 stood at -$53.3 million (down 177.0% YoY), while the FY2025 annual figure was -$30.3 million, down 204.97% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$11.3 million, up from -$34.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $107.8 million in Q1 2023, with the low at -$197.3 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $15.3 million (2022), against an average of $4.7 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 5783.15% in 2022, then soared 604.39% in 2023.
• Arcutis Biotherapeutics' Cash from Investing Activities stood at $42.2 million in 2022, then sank by 247.36% to -$62.2 million in 2023, then jumped by 156.08% to $34.9 million in 2024, then plunged by 198.0% to -$34.2 million in 2025, then soared by 66.85% to -$11.3 million in 2026.
• Business Quant data shows ARQT's Cash from Investing Activities at -$11.3 million in Q1 2026, -$34.2 million in Q4 2025, and -$25.2 million in Q3 2025.